Association of Risk of #Suicide Attempts With #Methylphenidate Treatment
http://jamanetwork.com/journals/jamapsychiatry/article-abstract/2645499
Patients with attention-deficit/hyperactivity disorder (ADHD) are at an increased risk of attempting suicide. Stimulants, such as methylphenidate hydrochloride, are the most common treatment for ADHD, but the association between their therapeutic use and suicide is unclear.
Conclusions and Relevance The incidence of suicide attempts was higher in the period immediately before the start of methylphenidate treatment. The risk remained elevated immediately after the start of methylphenidate treatment and returned to baseline levels during continuation of methylphenidate treatment. The observed higher risk of suicide attempts before treatment may reflect emerging psychiatric symptoms that trigger medical consultations that result in a decision to begin ADHD treatment.
Therefore, this study’s results do not support a causal association between methylphenidate treatment and suicide attempts
http://jamanetwork.com/journals/jamapsychiatry/article-abstract/2645499
Patients with attention-deficit/hyperactivity disorder (ADHD) are at an increased risk of attempting suicide. Stimulants, such as methylphenidate hydrochloride, are the most common treatment for ADHD, but the association between their therapeutic use and suicide is unclear.
Conclusions and Relevance The incidence of suicide attempts was higher in the period immediately before the start of methylphenidate treatment. The risk remained elevated immediately after the start of methylphenidate treatment and returned to baseline levels during continuation of methylphenidate treatment. The observed higher risk of suicide attempts before treatment may reflect emerging psychiatric symptoms that trigger medical consultations that result in a decision to begin ADHD treatment.
Therefore, this study’s results do not support a causal association between methylphenidate treatment and suicide attempts
#Methylphenidate for #Apathy in Community-Dwelling Older Veterans With Mild #Alzheimer ’s Disease: A Double-Blind, Randomized, Placebo-Controlled Trial
http://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.2017.17030316
Apathy is a common behavioral problem in Alzheimer’s disease. Apathy has profound consequences, such as functional impairment, higher service utilization, higher caregiver burden, and increased mortality. The authors’ objective was to study the effects of methylphenidate on apathy in Alzheimer’s disease Participants were all men (77 years old, SD=8). After adjusting for baseline, the methylphenidate group had significantly greater improvement in apathy than the placebo group at 4 weeks, 8 weeks, and 12 weeks. At 12 weeks, there was also greater improvement in cognition, functional status, caregiver burden, CGI scores, and depression in the methylphenidate group compared with the placebo group.
Conclusions:
Methylphenidate improved apathy in a group of community-dwelling veterans with mild Alzheimer’s disease. Methylphenidate also improved cognition, functional status, caregiver burden, CGI scores, and depression
http://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.2017.17030316
Apathy is a common behavioral problem in Alzheimer’s disease. Apathy has profound consequences, such as functional impairment, higher service utilization, higher caregiver burden, and increased mortality. The authors’ objective was to study the effects of methylphenidate on apathy in Alzheimer’s disease Participants were all men (77 years old, SD=8). After adjusting for baseline, the methylphenidate group had significantly greater improvement in apathy than the placebo group at 4 weeks, 8 weeks, and 12 weeks. At 12 weeks, there was also greater improvement in cognition, functional status, caregiver burden, CGI scores, and depression in the methylphenidate group compared with the placebo group.
Conclusions:
Methylphenidate improved apathy in a group of community-dwelling veterans with mild Alzheimer’s disease. Methylphenidate also improved cognition, functional status, caregiver burden, CGI scores, and depression